前立腺癌患者における女性ホルモンの血中アンチトロンビン3に対する影響

Abstract

39例に於て, 血中アンチトロンビン3(AT3)値を合成基質法にて測定した.未治療24, 女性ホルモン治療後6, 酢酸クロルマジノン投与後9で, 未治療群におけるAT3値は, 6例を除き正常範囲内であり, 女性ホルモン治療1ヵ月後には23.5%に低下を示し, 1週間ですでに始まっていた.ジエチルスチルベストロール(DESP) 250 mg静脈内投与6例中2例はAT3値の低下は全く示さず, 女性ホルモン治療にても無効の症例がある.DESP 50 mg, エチニルエストラジオール0.5 mg程の少量女性ホルモンでもAT3値が低下したものがあるが, 継続治療の6ヵ月後に正常化するのが一般的である

Since reduced antithrombin III (AT III) activity are associated with increased risk of thromboembolism, we have determined it in 39 patients with prostatic carcinoma. Pre-treatment levels were determined in 24 patients, 6 additional patients with prostatic carcinoma on estrogen treatment and 9 patients on chlormadinone acetate (CMA) therapy. In 12 of 24 patients we studied AT III levels before and after estrogen therapy was initiated. A significant decrease in AT III activity of 23.5% was found after one month on estrogen treatment, the patients on low doses of estrogen. Recovery of the levels of AT III was found after 6 months treatment even in in 5 of 6 patients who had shown depression of AT III levels initially. CMA treatment did not cause its depression. AT III levels was not connected with the stage of the disease or age of the patient.